Related Experiment Video
Updated: Aug 24, 2026
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in
Marcello Deraco1, Dario Baratti, Maria Grazia Inglese
1Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan, Italy. marcello.deraco@istitutotumori.mi.it
Background:
Pseudomyxoma peritonei (PMP) is a rare disease with a poor prognosis characterized by a complete redistribution of mucin within the peritoneal cavity. The aim of this multicentric study was to evaluate the survival, morbidity, toxicity, and mortality of patients with PMP treated by cytoreductive surgery (CRS) with intraperitoneal hyperthermic perfusion (IPHP).
Methods:
Thirty-three patients with PMP (21 males and 12 females) were enrolled in a phase II clinical trial. One patient underwent surgery twice because of disease recurrence. CRS was performed with peritonectomy procedures. The closed abdomen technique was employed for IPHP with use of cisplatin (25 mg/m2/L) plus mitomycin-C (3.3 mg/m2/L) for 60 minutes under hyperthermic conditions (42.5 degrees C).
Results:
Thirty-one patients (92%) were optimally cytoreduced. Five-year overall survival, progression-free survival, and locoregional progression-free survival rates were 97%, 43%, and 59%, respectively. Grade II and grade III morbidity was observed in 5 patient (15%) and 6 patients (18%), respectively. There was one treatment-related death (3%), 21 days after treatment.
Conclusions:
CRS associated with IPHP permitted complete tumor removal with an acceptable morbidity and mortality for patients with PMP. This study confirms the efficacy of the combined treatment in terms of long-term survival and local disease control.
Insights
Cytoreductive surgery (CRS) combined with intraperitoneal hyperthermic perfusion (IPHP) offers improved survival for patients with pseudomyxoma peritonei (PMP). This treatment approach demonstrates efficacy in long-term survival and local disease control for this rare condition.
Area of Science:
- Oncology
- Surgical Oncology
Background:
- Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by mucin accumulation in the peritoneal cavity.
- PMP typically has a poor prognosis, necessitating effective treatment strategies.
Purpose of the Study:
- To evaluate the survival, morbidity, toxicity, and mortality associated with cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP) in PMP patients.
- To assess the efficacy of combined CRS and IPHP for pseudomyxoma peritonei treatment.
Main Methods:
- A phase II multicentric clinical trial involving 33 patients with PMP.
- CRS involved peritonectomy procedures, followed by closed abdomen IPHP using cisplatin and mitomycin-C at 42.5°C for 60 minutes.
Main Results:
- 92% of patients achieved optimal cytoreduction.
- Five-year survival rates were 97% overall, 43% progression-free, and 59% locoregional progression-free.
- Morbidity rates were 15% (Grade II) and 18% (Grade III), with one treatment-related death (3%).
Conclusions:
- CRS with IPHP enables complete tumor removal in PMP patients.
- The combined treatment demonstrates acceptable morbidity and mortality rates.
- This approach is effective for achieving long-term survival and local disease control in pseudomyxoma peritonei.
